Hubei Biocause Pharmaceutical Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
1,765
- Stock Symbol
-
000627
- Investments
-
6
- Share Price
-
$0.36
- (As of Tuesday Closing)
Hubei Biocause Pharmaceutical General Information
Description
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Contact Information
Website
www.tianmaogroup.netCorporate Office
- No.122 Yangwan Road
- Jingmen
- Hubei, 448000
- China
Corporate Office
- No.122 Yangwan Road
- Jingmen
- Hubei, 448000
- China
Hubei Biocause Pharmaceutical Stock Performance
As of 08-Jul-2025, Hubei Biocause Pharmaceutical’s stock price is $0.36. Its current market cap is $1.78B with 4.9B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.36 | $0.38 | $0.22 - $0.75 | $1.78B | 4.9B | 67M | -$0.02 |
Hubei Biocause Pharmaceutical Financials Summary
As of 30-Sep-2024, Hubei Biocause Pharmaceutical has a trailing 12-month revenue of $5.86B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 4,390,753 | 3,766,320 | 4,155,964 | 4,846,148 |
| Revenue | 5,862,554 | 7,009,736 | 7,315,139 | 7,615,719 |
| EBITDA | (237,276) | (242,496) | 55,245 | 73,882 |
| Net Income | (107,531) | (92,123) | 40,693 | 72,899 |
| Total Assets | 40,664,778 | 42,594,579 | 41,830,141 | 41,402,546 |
| Total Debt | 0 | 0 | 0 | 0 |
Hubei Biocause Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hubei Biocause Pharmaceutical Investments & Acquisitions (6)
Hubei Biocause Pharmaceutical’s most recent deal was a Later Stage VC with Pharnex. The deal was made on 09-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pharnex | 09-May-2024 | Later Stage VC | Media and Information Services (B2B) | ||
| Granules Biocause Pharmaceuticals | 04-Feb-2020 | Secondary Transaction - Private | Drug Discovery | ||
| Guohua Life Insurance | 30-Aug-2019 | Secondary Transaction - Private | Life and Health Insurance | ||
| Guohua Life Insurance | 22-Mar-2016 | Merger/Acquisition | Life and Health Insurance | ||
| AXA Tianping Property Insurance | 10-Mar-2016 | Secondary Transaction - Private | Multi-line Insurance |
Hubei Biocause Pharmaceutical ESG
Risk Overview
Risk Rating
Updated June, 20, 2025
43.8 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 420
Rank
Percentile
Hubei Biocause Pharmaceutical Exits (1)
Hubei Biocause Pharmaceutical’s most recent exit was on 10-Mar-2016 from AXA Tianping Property Insurance. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| AXA Tianping Property Insurance | 10-Mar-2016 | Completed |
|
Hubei Biocause Pharmaceutical Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Guohua Life Insurance | Shanghai, China | 2007 | |
| Granules Biocause Pharmaceuticals | Jingmen, China | 2007 |
Hubei Biocause Pharmaceutical FAQs
-
When was Hubei Biocause Pharmaceutical founded?
Hubei Biocause Pharmaceutical was founded in 1993.
-
Where is Hubei Biocause Pharmaceutical headquartered?
Hubei Biocause Pharmaceutical is headquartered in Hubei, China.
-
What is the size of Hubei Biocause Pharmaceutical?
Hubei Biocause Pharmaceutical has 1,765 total employees.
-
What industry is Hubei Biocause Pharmaceutical in?
Hubei Biocause Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Hubei Biocause Pharmaceutical a private or public company?
Hubei Biocause Pharmaceutical is a Public company.
-
What is Hubei Biocause Pharmaceutical’s stock symbol?
The ticker symbol for Hubei Biocause Pharmaceutical is 000627.
-
What is the current stock price of Hubei Biocause Pharmaceutical?
As of 08-Jul-2025 the stock price of Hubei Biocause Pharmaceutical is $0.36.
-
What is the current market cap of Hubei Biocause Pharmaceutical?
The current market capitalization of Hubei Biocause Pharmaceutical is $1.78B.
-
What is Hubei Biocause Pharmaceutical’s current revenue?
The trailing twelve month revenue for Hubei Biocause Pharmaceutical is $5.86B.
-
What is Hubei Biocause Pharmaceutical’s annual earnings per share (EPS)?
Hubei Biocause Pharmaceutical’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
